AstraZeneca and Sanofi Pasteur forge €615m alliance to develop infant respiratory drug MEDI8897
AstraZeneca’s biotech arm, MedImmune, and Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi, have entered into a significant research and development collaboration. The ... Read More
FDA approves Serenity Pharmaceuticals’ Noctiva for nocturnal polyuria
Serenity Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Noctiva (desmopressin acetate), a nasal spray developed to treat nocturnal polyuria syndrome in ... Read More
Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial
Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase ... Read More
FDA approves CeloNova Cobra PzF coronary stent system
The US Food and Drug Administration (FDA) has approved the Cobra PzF nanocoated coronary stent system developed by Texas medical device maker CeloNova BioSciences. Approval ... Read More
Roche’s Perjeta shows significant promise in phase 3 breast cancer trial
Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy. This ... Read More
FDA approves Lexicon Pharmaceuticals’ Xermelo for carcinoid syndrome diarrhea
Lexicon Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its oral drug Xermelo (telotristat ethyl) 250mg, to be used in ... Read More
Exonics Therapeutics receives $5m seed funding to advance Duchenne Muscular Dystrophy therapy
Exonics Therapeutics, a biotechnology firm based in Boston, Massachusetts, has secured $5 million in seed funding from CureDuchenne Ventures, a subsidiary of the nonprofit Duchenne ... Read More
Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial
Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More
Symic Bio initiates SB-030 Phase 1/2a study in peripheral artery disease
Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase 1/2a clinical study, dubbed SHIELD, for its ... Read More
FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority ... Read More